NCT04260698CompletedPhase 3
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 5 Feb 2020
- Start date
- 8 Jul 2020
- Primary completion date
- 8 May 2025
- Lead sponsor
- Gamida Cell ltd
- Diseases
- Childhood cancers
- NCT number
- NCT04260698
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 36
- From 8 Jul 2020 to the primary completion date, 8 May 2025
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Donor specific anti-HLA antibodies
- Medically unsuitable for transplant
Other
- Extensive bone marrow fibrosis
- Pregnancy
Who the study is looking for
- Patients must be at least 12 years of age
- Applicable disease criteria
- Patients must have one or two partially HLA-matched CBUs
- Back-up stem cell source
- Sufficient physiological reserves
- Females of childbearing potential agree to use appropriate method of contraception
- Signed written informed consent
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke University Medical Center Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
| UCLA Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Loyola University, Cardinal Bernardin Cancer Center Coordinator of this site? Confirm its status | Maywood | United States | Unknown status |
| University of Minnesota/Masonic Cancer Center Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
| Stanford University Cancer Institute Coordinator of this site? Confirm its status | Palo Alto | United States | Unknown status |
| Oregon Health Science University Coordinator of this site? Confirm its status | Portland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.